We serve Chemical Name:4-Chloro-6-fluoro-2-(trifluoromethyl)quinoline CAS:59611-55-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Chloro-6-fluoro-2-(trifluoromethyl)quinoline
CAS.NO:59611-55-1
Synonyms:MFCD00276579;Quinoline, 4-chloro-6-fluoro-2-(trifluoromethyl)-;4-Chloro-6-fluoro-2-(trifluoromethyl)quinoline;4-chloro-6-fluoro-2-trifluoromethylquinoline
Molecular Formula:C10H4ClF4N
Molecular Weight:249.592
HS Code:2933499090
Physical and Chemical Properties:
Melting point:78-81ºC
Boiling point:240.5±35.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.538
PSA:12.89000
Exact Mass:248.996841
LogP:4.02
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD00276579 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-chloro-6-fluoro-2-trifluoromethylquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00276579 Use and application,Quinoline, 4-chloro-6-fluoro-2-(trifluoromethyl)- technical grade,usp/ep/jp grade.
Related News: Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. 4-Chloro-6-fluoro-2-(trifluoromethyl)quinoline manufacturer A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 4-Chloro-6-fluoro-2-(trifluoromethyl)quinoline supplier In October 2020, the Trump administration ordered $375 million worth of Lilly’s COVID-19 antibody therapy bamlanivimab, which is manufactured at the Branchburg plant. 4-Chloro-6-fluoro-2-(trifluoromethyl)quinoline vendor Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. 4-Chloro-6-fluoro-2-(trifluoromethyl)quinoline factory Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.